Improving targeted therapy for neuroendocrine tumors while protecting kidney health
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This study is looking at a new treatment for neuroendocrine tumors that uses special targeted therapy to help shrink tumors while protecting your kidneys, so you can get a safer and more effective plan tailored just for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10942787 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of a new type of targeted therapy for neuroendocrine tumors (NETs) that uses alpha-emitting radioligands. The approach aims to maximize tumor response rates while minimizing kidney damage, which can occur as a side effect of treatment. By investigating biomarkers of kidney injury and optimizing dosing regimens, the study seeks to develop a safer and more effective treatment protocol. Patients may benefit from a more personalized treatment plan that considers both tumor response and kidney health.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with neuroendocrine tumors who are considering or undergoing alpha-emitter radioligand therapy.
Not a fit: Patients with neuroendocrine tumors who are not eligible for radioligand therapy or those with pre-existing severe kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with neuroendocrine tumors while reducing the risk of kidney damage.
How similar studies have performed: Other research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.